Traders Watching VIVUS (VVUS) and Other Obesity Drug Makers Ahead of Today's CV Panel (OREX) (ARNA)
Tweet
Share
E-mail
Get Alerts VVUS Hot Sheet
Join SI Premium – FREE
The volatility in obesity drug makers is expected to continue as the FDA's 2-day CV study requirement panel starts today. Briefing documents were posted on March 26.
While VIVUS' (Nasdaq: VVUS) Qnexa received backing from an FDA panel on February 22, there is concerns about a 2-stage pre-approval CV study. Another alternative would be a post-approval CV study, or best case no study at all.
While VIVUS is currently seen in the lead to get their obesity drug to market, Orexigen Therapeutics' (NASDAQ: OREX) Contrave could still beat it to the market if a CV study is required.
In addition to VIVUS and Orexigen, Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) has an obesity treatment. However, its shares were downgraded earlier today.
The scheduled Prescription Drug User Fee Act (PDUFA) date for Qnexa is April 17, 2012.
While VIVUS' (Nasdaq: VVUS) Qnexa received backing from an FDA panel on February 22, there is concerns about a 2-stage pre-approval CV study. Another alternative would be a post-approval CV study, or best case no study at all.
While VIVUS is currently seen in the lead to get their obesity drug to market, Orexigen Therapeutics' (NASDAQ: OREX) Contrave could still beat it to the market if a CV study is required.
In addition to VIVUS and Orexigen, Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) has an obesity treatment. However, its shares were downgraded earlier today.
The scheduled Prescription Drug User Fee Act (PDUFA) date for Qnexa is April 17, 2012.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Anthropic plans IPO potentially exceeding SpaceX's $86B record - Bloomberg
- Bessent on bonds: buyback could be more than 4 billion - CNBC
- Trump: nominate Heidi Overton, MD, PhD, as our next FDA commissioner
Create E-mail Alert Related Categories
FDA, Momentum Movers, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
